CDK9 inhibitors in acute myeloid leukemia

116Citations
Citations of this article
104Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Current treatment for acute myeloid leukemia (AML) is less than optimal, but increased understanding of disease pathobiology and genomics has led to clinical investigation of novel targeted therapies and rational combinations. Targeting the cyclin-dependent kinase 9 (CDK9) pathway, which is dysregulated in AML, is an attractive approach. Inhibition of CDK9 leads to downregulation of cell survival genes regulated by super enhancers such as MCL-1, MYC, and cyclin D1. As CDK9 inhibitors are nonselective, predictive biomarkers that may help identify patients most likely to respond to CDK9 inhibitors are now being utilized, with the goal of improving efficacy and safety.

Cite

CITATION STYLE

APA

Boffo, S., Damato, A., Alfano, L., & Giordano, A. (2018, February 23). CDK9 inhibitors in acute myeloid leukemia. Journal of Experimental and Clinical Cancer Research. BioMed Central Ltd. https://doi.org/10.1186/s13046-018-0704-8

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free